跳轉至內容
Merck
  • Population biology of intestinal enterococcus isolates from hospitalized and nonhospitalized individuals in different age groups.

Population biology of intestinal enterococcus isolates from hospitalized and nonhospitalized individuals in different age groups.

Applied and environmental microbiology (2014-12-31)
Ana P Tedim, Patricia Ruiz-Garbajosa, Jukka Corander, Concepción M Rodríguez, Rafael Cantón, Rob J Willems, Fernando Baquero, Teresa M Coque
摘要

The diversity of enterococcal populations from fecal samples from hospitalized (n = 133) and nonhospitalized individuals (n = 173) of different age groups (group I, ages 0 to 19 years; group II, ages 20 to 59 years; group III, ages ≥60 years) was analyzed. Enterococci were recovered at similar rates from hospitalized and nonhospitalized persons (77.44% to 79.77%) of all age groups (75.0% to 82.61%). Enterococcus faecalis and Enterococcus faecium were predominant, although seven other Enterococcus species were identified. E. faecalis and E. faecium (including ampicillin-resistant E. faecium) colonization rates in nonhospitalized persons were age independent. For inpatients, E. faecalis colonization rates were age independent, but E. faecium colonization rates (particularly the rates of ampicillin-resistant E. faecium colonization) significantly increased with age. The population structure of E. faecium and E. faecalis was determined by superimposing goeBURST and Bayesian analysis of the population structure (BAPS). Most E. faecium sequence types (STs; 150 isolates belonging to 75 STs) were linked to BAPS groups 1 (22.0%), 2 (31.3%), and 3 (36.7%). A positive association between hospital isolates and BAPS subgroups 2.1a and 3.3a (which included major ampicillin-resistant E. faecium human lineages) and between community-based ampicillin-resistant E. faecium isolates and BAPS subgroups 1.2 and 3.3b was found. Most E. faecalis isolates (130 isolates belonging to 58 STs) were grouped into 3 BAPS groups, BAPS groups 1 (36.9%), 2 (40.0%), and 3 (23.1%), with each one comprising widespread lineages. No positive associations with age or hospitalization were established. The diversity and dynamics of enterococcal populations in the fecal microbiota of healthy humans are largely unexplored, with the available knowledge being fragmented and contradictory. The study offers a novel and comprehensive analysis of enterococcal population landscapes and suggests that E. faecium populations from hospitalized patients and from community-based individuals differ, with a predominance of certain clonal lineages, often in association with elderly individuals, occurring in the hospital setting.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
氯霉素,大包装, ≥98% (HPLC)
Sigma-Aldrich
氨苄西林, anhydrous, 96.0-102.0% (anhydrous basis)
Sigma-Aldrich
红霉素, BioReagent, suitable for cell culture
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Sigma-Aldrich
氯霉素,大包装, BioReagent, suitable for plant cell culture
USP
左氧氟沙星, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
环丙沙星, ≥98% (HPLC)
Sigma-Aldrich
氯霉素,大包装, meets USP testing specifications
Sigma-Aldrich
Erythromycin standard solution, 1 mg/mL in H2O
USP
氨苄西林, United States Pharmacopeia (USP) Reference Standard
USP
红霉素, United States Pharmacopeia (USP) Reference Standard
Supelco
环丙沙星, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
红霉素, potency: ≥850 μg per mg
Supelco
氯霉素,大包装, VETRANAL®, analytical standard
Sigma-Aldrich
氨苄西林, meets USP testing specifications
Supelco
红霉素, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
氨苄西林, analytical standard
Sigma-Aldrich
红霉素, meets USP testing specifications
Supelco
Levofloxacin, analytical standard
Supelco
环丙沙星, VETRANAL®, analytical standard
环丙沙星, European Pharmacopoeia (EP) Reference Standard
氯霉素,大包装, European Pharmacopoeia (EP) Reference Standard
氨苄西林, anhydrous, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
红霉素, tested according to Ph. Eur.
红霉素, for microbiological assay, European Pharmacopoeia (EP) Reference Standard